<DOC>
	<DOCNO>NCT00139737</DOCNO>
	<brief_summary>To provide treatment eligible subject successfully complete one follow phase III ziprasidone study , A1281028 , A1281044 , A1281045 ( NCT00136994 ) A1281088 ( NCT00143351 ) .</brief_summary>
	<brief_title>Extension Study : Evaluating Safety Oral Ziprasidone Treatment Subjects With Schizophrenia</brief_title>
	<detailed_description />
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Ziprasidone</mesh_term>
	<criteria>Subjects successfully complete ziprasidone clinical study Patients hospitalise acute psychiatric service Written , inform consent participation . Female patient risk pregnancy must avoid remain pregnant ; adequate method contraception ( intrauterine device , implanted contraceptive , oral contraceptive condom ) must initiate continued Psychiatric : Subjects immediate risk commit harm self others Subjects require concurrent treatment nonstudy antipsychotic agent Subjects require treatment antidepressant mood stabilizer General : Subjects history clinically significant and/or currently relevant hematological , renal ( include single kidney ) , hepatic , gastrointestinal , endocrine ( except current adequately treat hypo hyperthyroidism ) , pulmonary ( exclude chronic bronchitis , mild emphysema chronic obstructive pulmonary disease ) , dermatological , oncological , neurological disease , exclude tardive dyskinesia include form epilepsy ( febrile convulsion childhood acceptable ) . The subject know prior malignant disease eligible cure prior skin cancer ( exclude melanoma ) . Controlled Type II diabetes ( glucose &lt; 180 mg/100 ml screen baseline dietary oral hypoglycemic treatment ) consider significant medical illness would exclude subject study Acute chronic heart disease Clinically significant ECG abnormality Subjects QTc &gt; = 500 msec ( subject QTc &gt; = 450 msec &lt; 500 msec discuss cardiologist responsible center involve ) Concomitant treatment medication prolong QTc interval ( please review prescribe information treatment ) Subjects serum K+ Mg++ outside normal range Subject confirm laboratory value deviate upper low limit normal prior study entry , except clinically insignificant deviation determine investigator Known serological evidence HIV , acute chronic hepatitis ( transaminase level higher three time upper limit ) Pregnant lactate woman Subjects intend donate blood blood product 4 week prior study , study 30 day study end Subjects unable unlikely follow study protocol Subjects history neuroleptic malignant syndrome develop administration antipsychotic compound Known hypersensitivity ziprasidone lactose</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>August 2010</verification_date>
	<keyword>Open-label extension Ziprasidone study Schizophrenia</keyword>
</DOC>